# XIENCE 28 Global Study

Study · id `cardio:ct-nct03355742` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03355742](<https://clinicaltrials.gov/study/NCT03355742>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03355742

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 963 participants.

## Technical summary

Registry record NCT03355742. Allocation not applicable; no masking; primary purpose treatment. Start 2018-02-09 (actual); primary completion 2019-10-24 (actual). Results posted on 2021-02-08.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 963 participants (enrolled count; ClinicalTrials.gov record NCT03355742, source copy `cardio:ctgov-nct03355742-2021-03-04`, retrieved 2026-10-26)
- Started: 2018-02-09 (actual) (ClinicalTrials.gov record NCT03355742, source copy `cardio:ctgov-nct03355742-2021-03-04`, retrieved 2026-10-26)
- Primary completion: 2019-10-24 (actual) (ClinicalTrials.gov record NCT03355742, source copy `cardio:ctgov-nct03355742-2021-03-04`, retrieved 2026-10-26)
- Completion: 2020-04-30 (actual) (ClinicalTrials.gov record NCT03355742, source copy `cardio:ctgov-nct03355742-2021-03-04`, retrieved 2026-10-26)
- Results first posted: 2021-02-08 (ClinicalTrials.gov record NCT03355742, source copy `cardio:ctgov-nct03355742-2021-03-04`, retrieved 2026-10-26)
- Countries: Austria; Belgium; China; Germany; Hong Kong SAR China; Italy; Netherlands; Portugal; Singapore; Spain; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT03355742, source copy `cardio:ctgov-nct03355742-2021-03-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03355742-2021-03-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: XIENCE 28 Global Study
- Condition: Bleeding Disorder
- Condition: Stroke, Ischemic
- Condition: Stroke Hemorrhagic
- Condition: Hematological Disease
- Condition: Thrombocytopenia
- Condition: Coagulation Disorder
- Condition: Anemia
- Condition: Renal Insufficiency
- Condition: Coronary Artery Disease
- Intervention (Device): XIENCE
- Intervention (Drug): DAPT
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 04b348304a4978b9707f92da7ded3f45a0b327df4ab40e4773cb73e0d58fafda
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
